Journal
CURRENT DIABETES REVIEWS
Volume 7, Issue 6, Pages 392-405Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157339911797579160
Keywords
Type 2 diabetes mellitus; Insulin; Thiazolidinediones; Sulphonylurea; Metformin; Glucagon-like peptide-1; Dipeptidyl peptidase-IV inhibitor; Bromocriptine; Alpha glucosidase inhibitor; Colesevelam
Categories
Ask authors/readers for more resources
While lifestyle modifications and metformin are the cornerstone of the initial management of type 2 diabetes mellitus, there is an increasing array of second and third-line pharmacological agents for this condition. These include sulphonylureas, insulin, thiazolidinediones and alpha-glucosidase inhibitors, with the more recent addition of glucagonlike peptide-1 agonists, dipeptidyl peptidase-IV inhibitors and pramlintide. Moreover, insulin analogues that better simulate endogenous insulin secretion have been developed. This review aims to provide an update on the current pharmacological management of type 2 diabetes mellitus, and to highlight the benefits and limitations of each treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available